MedicineOncologyPharmacotherapyClinical ImmunologyHematologic OncologyImmunopathologyAutoimmune DiseasesAutoimmune Hematologic DiseaseHematologic Malignancy TherapyImmune-mediated DiseaseImmune-related Adverse EventsInterferon-based TherapyChronic Myeloid Leukemia TherapyInterferon Alfa TherapyInterferon-mediated Pathology
We describe a patient with chronic myeloid myeloid leukemia (CML) on tow-dose treatment with interferon (IFN) who developed systemic sarcoidosis, a rare IFN-related side effect, while in complete cytogenetic remission. We chose to continue IFN and to treat the sarcoidosis with prednisone. After eight months, the CML is still in complete cytogenetic remission and the sarcoidosis is almost completely resolved.
2
Sarcoidosis induced by interferon therapy for chronic myelogenous leukaemia
Masayuki Kikawada, Yuichi Ichinose, Akira Kunisawa et al. · Respirology · 1998 · 40 citations
Medicine, Immunology, Pathology +14